59
Module #2 http://www. growthhouse .org/ stanford END-OF-LIFE CARE: Module 2 Pain Management

Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Embed Size (px)

Citation preview

Page 1: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

END-OF-LIFE CARE:Module 2

Pain Management

Page 2: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Case of Mrs. Dolores Long

Mrs. Dolores Long is a 70-year old widowed African American female who was recently diagnosed with lung carcinoma and metastasis to bone. She is being admitted to the hospital for a round of chemotherapy.A medical resident performs the admission H&P. Mrs. Long denies any symptoms. Physical examination is unremarkable. Mental status exam is significant for flat affect and poor eye contact. The resident finishes the exam and leaves the room. Mrs. Long’s daughter steps outside with the resident and explains that her mother has complained of severe pain and has become sedentary and withdrawn. She has refused the acetaminophen with codeine that was prescribed because she doesn’t want to “get hooked,” and the pills don’t help anyway.The resident is surprised, as Mrs. Long did not appear to be in pain. He explains that “nothing more can be done” for the pain, as strong narcotics like morphine might cause her to stop breathing and NSAIDs like ibuprofen could cause GI bleeding. However, psychiatry will be consulted to evaluate her depression.

Page 3: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Learning Objectives

Recognize and address barriers to effective EOL pain care

Develop a better understanding of attitudes and beliefs about pain management

Improve your knowledge and skills in assessing and treating pain

Incorporate this content into your clinical teaching

Page 4: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Outline of Module

Background

Barriers to treating pain

Pain Assessment

Non-pharmacologic treatment approaches

Break

Pharmacologic strategies

Pain medications

Application exercise

Summary and goals

Page 5: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Pain in the Hospitalized Seriously Ill

50% of conscious patients were in moderate to severe pain at least half the time in the three days prior to death

SUPPORT Study (1995), N = 9105 patients

Page 6: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Pain in Nursing Home Patients

• 30% reported daily pain• 26% of these patients received no analgesia• Only 26% of them received strong opioids

What predicted inadequate pain management?• Advanced age: >85 years old• Poor cognitive function• Minority status

Bernabei (1998), N = 13,625 cancer patients

Page 7: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Pain in Outpatients

• 67% outpatients with metastatic CA were in pain• 42% of those not given adequate analgesic therapy

What predicted inadequate pain management?• Discrepancy between patient and MD assessment of

pain• Advanced age: >70 years old• Female• Better performance status• Minorities

Cleeland (1994), N = 1308

Page 8: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Pain in 103 Children who Died of Cancer or its Complications

• 89% died while suffering pain or other symptoms

• Of those whose pain was treated, treatment was successful in only 27%

Wolfe, 2000

Page 9: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Brainstorm

What makes pain so difficult to treat?

Page 10: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Six Major Barriers to Adequate Pain Care

• Myth: That addiction is a common result of treating pain with opioids

• Regulatory and legal concerns• System barriers• Deficits in knowledge and education• Fear of side effects• Assessment challenges

Page 11: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Definitions

• Addiction: Psychological dependence on a drug. Drug-seeking behavior despite adverse consequences

• Physical Dependence: Development of physical withdrawal reaction upon discontinuation or antagonism of a drug

• Tolerance: Need to increase amount of drug to obtain the same effect

• Pseudoaddiction: Behavior suggestive of addiction occurring as a result of undertreated pain

Page 12: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Barrier #1: The Myth of Addiction

• Addiction differs from chemical dependence, tolerance, and pseudoaddiction

• Increased use of opioid analgesics for pain does not appear to contribute to increases in opioid abuse (Joranson, 2000)

• Fears are exaggerated due to referral bias• Pseudoaddiction complicates the picture• Increased opioid requirement is usually related

to progression of disease, not tolerance

Page 13: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Barrier #2: Regulatory and Legal Concerns

• Physicians are wary of prescribing controlled substances for fear of criminal and/or licensing sanctions– Risk is very low if indication and response are

properly documented

• Regulatory policies that control opioids get in the way– Triplicates– Renewal policies

Page 14: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

#3 System Barriers

• Lack of systemic use of practice guidelines• Pain management historically has not been

incorporated into quality management structure• Many institutions still lack pain and/or palliative

care services

Page 15: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Barrier #4: Deficits in Knowledge and Education

• In patients, families, physicians, and other health care professionals

• Pain management is still rarely addressed in medical school curricula

• It is rarely included in textbooks– < 2% medical textbook content (Rabow, 2000)– < 5% nursing textbook pages (Ferrell, 1999)

• Physicians lack awareness of their own knowledge deficits in pain management

Page 16: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Barrier #5: Bad Side Effects of Opioids - Key Points

• Pain is a partial antagonist to respiratory depression and CNS sedation

• Respiratory depression, sedation, and N&V relate more to changing blood serum levels of opioids than the steady state dose

• Pain management and constipation relate to steady state dosing, not the rising blood opioid level– Treat prophylactically and continually

Page 17: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Barrier #6: Assessment Challenges

• Health care professionals are more comfortable measuring objective data

• We lack a scanner that is more accurate than patient report

Page 18: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Assessment of Pain:Key Dimensions

Mechanism• Neuropathic pain

Abnormal state of central or peripheral nervous system gives rise to pain

• Nociceptive pain

Nerves responding appropriately to a painful stimulus

Timeline• Acute• Chronic

Page 19: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

We are All ‘Color-blind’ to Chronic Pain

Patients’ assessments

correlated with those of:

0-2

Little or no pain

3-6

Moderate pain

7-10

Severe pain

Nurse 82% 51% 7%

House Officer 66% 26% 21%

Onc Fellow 70% 29% 27%

Caregiver 79% 37% 13%

Page 20: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

A Tool to Help Assess Pain

N - Number of pains?

O - Origin/causes?

P - Palliates, potentiates?

Q - Quality?

R - Radiation?

S - Severity, suffering?

T - Timing, trend?

Page 21: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Neuropathic Pain

• Origin: – Nerve damage

• Palliates/potentiates: – Set off by unusual stimuli, light touch, wind on skin,

shaving (trigeminal neuralgia)

• Quality: – Electric, burning, tingling, pins & needles, shooting

(system isn’t working right)

• Radiation: – Nerve-related pattern

Page 22: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Nociceptive Pain

• Origin:– Tissue damage

• Palliates/potentiates:– Worse with stress, pressure– Responds better to opioids, NSAIDs

• Quality:– Sharp, dull, stabbing, pressure, ache, throbbing

• Radiation:– Occasionally radiates (less well-defined), but not

along an obvious nerve distribution

Page 23: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Visual Analog Scale

1-3 Tolerable

4-6 Change therapy soon

7-10 Emergency SOS - change therapy now

Page 24: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Suffering

“A state of severe distress associated with events that threaten the intactness of the person”

Cassell,1982

• Subjective: No way to measure it• Significantly diminishes quality of life

Page 25: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Back to the Mnemonic

• Timing:– When the pain occurs or with certain activities

• Trend:– Whether a pain is getting better or worse over time

Page 26: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Total Pain

P - Physical pain

A - Affective distress

I - Interpersonal distress

N - Non-acceptance, or spiritual distress

Page 27: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Discussion

Strategies for alleviating pain:

Non-pharmacologic options

Page 28: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Non-pharmacologic Approaches to Pain

Behavioral therapy

Spiritual counseling

Physical therapy

Psychotherapy

Splinting

Surgical correction

Cold packs

Meditation

Support groups

Radiation therapy

Acupuncture

Hypnosis

Cultural healing rituals

Heat packs

Prayer

Community resources

And others…

Page 29: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

General Principles for Alleviating Pain

• Assess with NOPQRST• Identify types(s) and location(s) of pain• Correct underlying cause, if possible• Consider special circumstances

– Avoid specific toxicities– Look for ‘two-fers’– Medication routes– Self-administered or by others

Page 30: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Pattern MatchingS

ever

ity

Time

Page 31: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

How Would You Treat the Acute Pain Pattern?

Sev

erity

Time

Page 32: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

What Would a Chronic Pain Pattern Look Like?

Sev

erity

Time

Page 33: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Treating Chronic Pain

Basal pain medicine plus a different therapy for spikes:

– Predictable spikes - Short-acting agent prior to event– Unpredictable spikes - Short-acting agent readily

available

Page 34: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Case Discussion

Chronic pain escalating at night - Why?

Page 35: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Brainstorm

How might we treat Mrs. Long’s pain?

Page 36: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Neuropathic Pain Medications

• Opioids, NSAIDs somewhat less effective• Classes of agents:

– Tricyclic for dysesthetic pain– Anticonvulsants for shooting pain– Steroids to decrease peri-tumor edema

• ‘Two-fers’ important in choice of agent(s)• Generally harder to treat than nociceptive pain

– More likely to need specialist expertise

Page 37: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

NSAIDs

• May be more effective than opioids with certain

forms of pain• Not necessarily less toxic than opioids• Toxicity can be minimized• For basal pain relief, consider longer-acting

agent for ease of dosing

Page 38: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Combination Drugs

• Advantages:– Aspirin or acetaminophen may act as co-analgesic– Lower level regulatory control

• Disadvantages:– Available in short-acting formulations only– ‘Combo wall’

Page 39: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Acetaminophen With Codeine

• Advantages:– Low regulatory control– Inexpensive– Widely available

• Disadvantages:– 10% cannot convert codeine to morphine– Many drugs interfere with conversion

Page 40: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Acetaminophen with Oxycodone, Hydrocodone

• Oxycodone combination contains 325 mg acetaminophen

• Hydrocodone combination contains 500 mg acetaminophen

• No clear advantage between the two• Dose equivalence is poorly established for

hydrocodone

Page 41: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Case Discussion

• Why didn’t Mrs. Long respond to acetaminophen with codeine?

Page 42: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Opioids

• Morphine• Oxycodone• Hydromorphone• Transdermal fentanyl

Page 43: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Principles of Opioid Use

• No ceiling effect• Dose to pain relief without side effects• Give orally when possible• Sub-cutaneous administration is basically

equivalent to intravenous (and preferable)• Treat constipation prophylactically

Page 44: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Morphine

• Advantages:– Inexpensive– Routes: PO, PR, IV, SC, lingual

• Disadvantages:– Histamine release– Side effects, toxicity in high dose/renal failure– ‘Psychological allergy’

• Formulation:Long-acting ‘wax matrix,’ short-acting liquid, tab

Page 45: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Standard Starting Dose

• For opioid-naïve, 5-10 mg PO q4 PRN• After getting an idea of the 24-hour dose, go

to long-acting• Or start with 15 mg q12 long-acting• There is no ceiling effect

Page 46: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Oxycodone

• Advantages:– Good alternative to morphine– Available PO: long-acting (q8-12) or short-acting– ? Less CNS alteration than with morphine– ? Less histamine release

• Disadvantages:– More expensive than morphine– No parenteral form available in the U.S.A.

Page 47: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Hydromorphone

• Advantages:– Available PO, IV, SC– Good alternative to morphine for parenteral use– No known toxic metabolites– Long-acting oral form now available

Page 48: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Transdermal Fentanyl

• Advantages– Non-enteral administration– Change q72h– Steady blood levels

• Disadvantages– Local skin problems– Delayed onset and offset– Cumbersome to titrate (only q72h)– 20% of people need it changed q48h– Expensive

Page 49: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Question

What were the general principles of opioid use we mentioned earlier?

Page 50: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Case Discussion

What do you suggest to help alleviate Mrs. Long’s pain?

What more do we need to know?

Page 51: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Case Discussion, Continued

Mrs. Long has bony pain in the hip that seems to be nociceptive

• What might this pain pattern look like?• What should we treat her with, and why?

Page 52: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Opioid Conversion

• This is a crucial skill in ELC• Traditionally, it was viewed as a task• It would be more correct to think of it as a

process

Page 53: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Using Opioid Conversion Tables

• Calculate 24h equivalent of old drug• Convert to 24h equivalent of new drug or route• Calculate new dosing interval• Divide 24h dose by new dosing interval• Round off this value• Account for residual drug

Page 54: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Application

• Mrs. Long is admitted to the hospital and can no longer take pills

• She has been taking sustained action oral morphine 60mg q12

• Her family just managed to get her to take her last dose 2 hours ago

• Her pain is well controlled• You want to start her on a SC infusion of

morphine

Page 55: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Warnings

• Most narcotic conversion charts are based on peak drug levels

• Increase on percentage basis not dosage: 25-50% per each 24 hours

• Dose to comfort or side effects (monitor)

Page 56: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Opioids May Differ

Opioids may differ from each other significantly in:

• Mechanism of action• Degree of cross-tolerance

Page 57: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Two Principles

In the conversion process:

• For the new drug, use basal doses initially• Be relatively liberal in your use of

breakthrough/short-acting doses

Page 58: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Conclusion

Practice!

Page 59: Http:// Module #2 END-OF-LIFE CARE: Module 2 Pain Management

Module #2http://www.growthhouse.org/stanford

Learning Objectives

Recognize and address barriers to effective pain care

Develop a better understanding of attitudes and beliefs about pain management

Improve your knowledge and skills in assessing and treating pain

Incorporate this content into your clinical teaching

.